BioMark Diagnostics Inc. (BUX.CN)
CAD 0.2
(0.0%)
CAD 0.2
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 649.18 Thousand CAD | -13.65% |
| 2022 | 751.83 Thousand CAD | 12.77% |
| 2021 | 666.68 Thousand CAD | 187.91% |
| 2020 | -758.35 Thousand CAD | -25.73% |
| 2019 | -603.13 Thousand CAD | -2916.6% |
| 2018 | -19.99 Thousand CAD | 45.42% |
| 2017 | -36.63 Thousand CAD | -109.46% |
| 2016 | -17.48 Thousand CAD | -23.75% |
| 2015 | -14.13 Thousand CAD | 92.8% |
| 2014 | -196.23 Thousand CAD | -113.3% |
| 2013 | -92 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 580.59 Thousand CAD | -10.56% |
| 2023 Q4 | 649.18 Thousand CAD | -3.18% |
| 2023 Q1 | 562.4 Thousand CAD | -25.2% |
| 2023 FY | 649.18 Thousand CAD | -13.65% |
| 2023 Q2 | 347.99 Thousand CAD | -38.12% |
| 2023 Q3 | 670.53 Thousand CAD | 92.69% |
| 2022 Q4 | 751.83 Thousand CAD | -2.91% |
| 2022 Q3 | 774.39 Thousand CAD | -6.7% |
| 2022 Q2 | 830.03 Thousand CAD | 34.85% |
| 2022 Q1 | 615.53 Thousand CAD | -7.67% |
| 2022 FY | 751.83 Thousand CAD | 12.77% |
| 2021 Q1 | -563.73 Thousand CAD | 25.66% |
| 2021 Q2 | -262.8 Thousand CAD | 53.38% |
| 2021 FY | 666.68 Thousand CAD | 187.91% |
| 2021 Q3 | 790.52 Thousand CAD | 400.81% |
| 2021 Q4 | 666.68 Thousand CAD | -15.67% |
| 2020 Q3 | -257.45 Thousand CAD | 31.03% |
| 2020 Q4 | -758.35 Thousand CAD | -194.56% |
| 2020 Q1 | -500.16 Thousand CAD | 17.07% |
| 2020 Q2 | -373.27 Thousand CAD | 25.37% |
| 2020 FY | -758.35 Thousand CAD | -25.73% |
| 2019 Q2 | -65.28 Thousand CAD | 57.92% |
| 2019 Q1 | -155.15 Thousand CAD | -676.0% |
| 2019 FY | -603.13 Thousand CAD | -2916.6% |
| 2019 Q4 | -603.13 Thousand CAD | -373.11% |
| 2019 Q3 | 220.83 Thousand CAD | 438.25% |
| 2018 Q3 | 945.82 Thousand CAD | 9.66% |
| 2018 Q4 | -19.99 Thousand CAD | -102.11% |
| 2018 FY | -19.99 Thousand CAD | 45.42% |
| 2018 Q1 | 726.7 Thousand CAD | 2083.81% |
| 2018 Q2 | 862.52 Thousand CAD | 18.69% |
| 2017 FY | -36.63 Thousand CAD | -109.46% |
| 2017 Q4 | -36.63 Thousand CAD | -106.39% |
| 2017 Q3 | 573 Thousand CAD | 54.1% |
| 2017 Q2 | 371.84 Thousand CAD | 13.64% |
| 2017 Q1 | 327.2 Thousand CAD | 1970.9% |
| 2016 Q1 | 421.95 Thousand CAD | 3085.83% |
| 2016 FY | -17.48 Thousand CAD | -23.75% |
| 2016 Q2 | 544.23 Thousand CAD | 28.98% |
| 2016 Q4 | -17.48 Thousand CAD | -746.92% |
| 2016 Q3 | -2065.00 CAD | -100.38% |
| 2015 Q1 | 102.85 Thousand CAD | 152.42% |
| 2015 Q3 | 331.71 Thousand CAD | 65.42% |
| 2015 Q4 | -14.13 Thousand CAD | -104.26% |
| 2015 FY | -14.13 Thousand CAD | 92.8% |
| 2015 Q2 | 200.53 Thousand CAD | 94.96% |
| 2014 FY | -196.23 Thousand CAD | -113.3% |
| 2014 Q2 | -1.00 CAD | -100.0% |
| 2014 Q3 | -5109.00 CAD | -510800.0% |
| 2014 Q4 | -196.23 Thousand CAD | -3740.97% |
| 2014 Q1 | 92 Thousand CAD | 0.0% |
| 2013 FY | -92 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Izotropic Corporation | 2.04 Million CAD | 68.279% |
| Sona Nanotech Inc. | 418.29 Thousand CAD | -55.196% |